Veraxa Biotech is trading 5.31% lower at $1.07, with no confirmed company-specific catalyst identified. - The company’s investor-relations page lists its latest release as a September 4 CFO appointment, not a new announcement on October 6, 2026. - Biotech ETF XBI was down 2.50% during the regular session, suggesting industry weakness may be adding pressure. - The broader market was higher, and a direct cause of the stock’s decline remains unconfirmed.